Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
Domains
Santé publique et épidémiologieOrigin | Files produced by the author(s) |
---|
_ |
Origin | Files produced by the author(s) |
---|
Gestionnaire HAL 3 Sorbonne Université : Connect in order to contact the contributor
https://hal.sorbonne-universite.fr/hal-03784773
Submitted on : Friday, September 23, 2022-12:49:35 PM
Last modification on : Wednesday, September 4, 2024-3:03:27 PM
Long-term archiving on : Saturday, December 24, 2022-6:44:32 PM